Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer
Clinical Colorectal Cancer · 2026
DOI: 10.1016/j.clcc.2026.03.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2026. Verfasst von Guillaume Roy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Hôpital Charles-LeMoyne, Greenfield Park, QC, Canada; Department of Medicine, University of Sherbrooke, Sherbroo…. Hauptthemen laut MEDLINE: Capecitabine, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Following the IDEA collaboration, the use of capecitabine and oxaliplatin (CAPOX regimen) for adjuvant colorectal cancer treatment has increased. While CAPOX is associated with higher rates of diarrhea, non-neutropenic enterocolitis (NNE) and related hospitalizations have not been well described. PATIENTS AND METHODS: We performed a retrospective cohort study of patients treated with adjuvant CAPOX, mFOLFOX6 (infusional 5-fluorouracil, leucovorin, and oxaliplatin), and capecitabine between 2015 and 2023 at 2 hospitals in Quebec, Canada. Data on demographics, oncologic treatments, and complications, including NNE (defined as grade ≥ 2 diarrhea with radiologic ileocolitis) were extracted. RESULTS: A total of 223 patients were included, 82.9% of patients had stage III colorectal cancer, 54.3% received CAPOX, and 40.8% mFOLFOX6. NNE occurred in 12.4% of patients treated with CAPOX versus 1.1% with mFOLFOX6 (odds ratio [OR] 12.736, P = .002). All NNE were grade 3 to 4 events and required hospitalization. The median time to CAPOX-induced NNE onset was 36 days after the first chemotherapy dose. Risk factors for NNE included CAPOX use (OR [vs. mFOLFOX6] OR 12.736, P = .002) and age over 65 years (OR 4.214, P = .006). No difference in relapse-free survival was observed for stage III patients with versus without NNE (hazard ratio 0.247, P = .167). CONCLUSION: NNE is a significant complication of CAPOX, particularly in patients over 65 years. It occurs early in the treatment course, leads to a high rate of hospitalization, and necessitates careful patient selection and close monitoring during early cycles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Hôpital Charles-LeMoyne, Greenfield Park, QC, Canada; Department of Medicine, University of Sherbrooke, Sherbrooke, QC, Canada. Electronic address: guillaume.roy10@usherbrooke.ca.
- Department of Internal Medicine, CHUS-Fleurimont, Sherbrooke, QC, Canada.
- Division of Hematology and Oncology, CHUS-Fleurimont, Sherbrooke, QC, Canada; Department of Medicine, University of Sherbrooke, Sherbrooke, QC, Canada.
- Division of Hematology and Oncology, Hôpital Charles-LeMoyne, Greenfield Park, QC, Canada; Department of Medicine, University of Sherbrooke, Sherbrooke, QC, Canada.
Zitieren
APA
Roy, G., Okde, R., Cull, O., Pool, G., & Boutin, M. (2026). Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.03.002
Vancouver
Roy G, Okde R, Cull O, Pool G, Boutin M. Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.03.002
BibTeX
@article{Roy2026,
author = {Roy, Guillaume and Okde, Rakan and Cull, Olivia and Pool, Giulia and Boutin, Mélina},
title = {Incidence and Risk Factors of Non-neutropenic Enterocolitis With Adjuvant Capecitabine and Oxaliplatin Chemotherapy in Colorectal Cancer},
journal = {Clinical Colorectal Cancer},
year = {2026},
doi = {10.1016/j.clcc.2026.03.002}
}
EUVIMED